The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients
Open accessAbstract
Paraneoplastic cerebellar degeneration (PCD) is a heterogeneous group of disorders characterized by subacute cerebellar ataxia, specific tumour types and (often) associated antineuronal antibodies. Nine specific antineuronal antibodies are associated with PCD. We examined the relative frequency of the antineuronal antibodies associated with PCD and compared the neurological symptoms and signs, associated tumours, disability and survival between groups of PCD with different antibodies. Also, we attempted to identify patient-, tumour- and treatment-related characteristics associated with functional outcome and survival. In a 12-year period, we examined >5000 samples for the presence of antineuronal antibodies. A total of 137 patients were identified with a paraneoplastic neurological syndrome and high titre (> or =400) antineuronal antibodies. Fifty (36%) of these patients had antibody-associated PCD, including 19 anti-Yo, 16 anti-Hu, seven anti-Tr, six anti-Ri and two anti-mGluR1. Because of the low number, the anti-mGluR1 patients were excluded from the statistical analysis. While 100% of patients with anti-Yo, anti-Tr and anti-mGluR1 antibodies suffered PCD, 86% of anti-Ri and only 18% of anti-Hu patients had PCD. All patients presented with subacute cerebellar ataxia progressive over weeks to months and stabilized within 6 months. The majority of patients in all antibody groups had both truncal and appendicular ataxia. The frequency of nystagmus and dysarthria was lower in anti-Ri patients (33 and 0%). Later in the course of the disease, involvement of non-cerebellar structures occurred most frequently in anti-Hu patients (94%). In 42 patients (84%), a tumour was detected. The most commonly associated tumours were gynaecological and breast cancer (anti-Yo and anti-Ri), lung cancer (anti-Hu) and Hodgkin's lymphoma (anti-Tr and anti-mGluR1). In one anti-Hu patient, a suspect lung lesion on CT scan disappeared while the PCD evolved. Seven patients improved by at least 1 point on the Rankin scale, while 16 remained stable and 27 deteriorated. All seven patients that improved received antitumour treatment for their underlying cancer, resulting in complete remission. The functional outcome was best in the anti-Ri patients, with three out of six improving neurologically and five were able to walk at the time of last follow-up or death. Only four out of 19 anti-Yo and four out of 16 anti-Hu patients remained ambulatory. Also, survival from time of diagnosis was significantly worse in the anti-Yo (median 13 months) and anti-Hu (median 7 months) patients compared with anti-Tr (median >113 months) and anti-Ri (median >69 months). Patients receiving antitumour treatment (with or without immunosuppressive therapy) lived significantly longer [hazard ratio (HR) 0.3; 95% confidence interval (CI) 0.1-0.6; P = 0.004]. Patients > or =60 years old lived somewhat shorter from time of diagnosis, although statistically not significant (HR 2.9; CI 1.0-8.5; P = 0.06).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Graus, F. (2001) · Brain · doi:10.1093/brain/124.6.1138 · Cited by 897
Dalmau, J., Graus, F., Rosenblum, M. K., & Posner, J. B. (1992) · MEDICINE · doi:10.1097/00005792-199203000-00001 · Cited by 819
Maloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
MD, K. P., Rosenblum, M. K., MS, H. K., & Posner, J. B. (1992) · Neurology · doi:10.1212/wnl.42.10.1931 · Cited by 608
CD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Szabo, A., Dalmau, J., Manley, G., Rosenfeld, M., Wong, E., Henson, J., Posner, J. B., & Furneaux, H. M. (1991) · Cell · doi:10.1016/0092-8674(91)90184-z · Cited by 553
Paraneoplastic Cerebellar Ataxia Due to Autoantibodies against a Glutamate Receptor
Smitt, P. S., Kinoshita, A., De Leeuw, B., Moll, W., Coesmans, M., Jaarsma, D., Henzen-Logmans, S., Vecht, C., De Zeeuw, C., Sekiyama, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001063420104 · Cited by 451
Self-citationAnti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer
Luque, F. A., Furneaux, H. M., Ferziger, R., Rosenblum, M. K., Wray, S. H., Schold, S. C., Glantz, M. J., Jaeckle, K. A., Biran, H., Lesser, M., et al. (1991) · Annals of Neurology · doi:10.1002/ana.410290303 · Cited by 402
Voltz, R., Gultekin, S. H., Rosenfeld, M. R., Gerstner, E., Eichen, J., Posner, J. B., & Dalmau, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402303 · Cited by 379
Neurologic Complications of Cancer
Wen, P. Y., & Glantz, M. J. (2003) · Neurologic Clinics · doi:10.1016/s0733-8619(02)00100-7 · Cited by 361
De Camilli, P., Thomas, A., Cofiell, R., Folli, F., Lichte, B., Piccolo, G., Meinck, H. M., Austoni, M., Fassetta, G., & Bottazzo, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2219 · Cited by 338
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies
Rojas-Marcos, I., Graus, F., Keime-Guibert, F., Reñé, R., Delattre, J., Ramon, J. M., Dalmau, J. O., & Posner, J. B. (2000) · Neurology · doi:10.1212/wnl.55.5.713 · Cited by 323
Buckanovich, R. J., Posner, J. B., & Darnell, R. B. (1993) · Neuron · doi:10.1016/0896-6273(93)90077-5 · Cited by 319
Albert, M. L., Austin, L. M., & Darnell, R. B. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<9::aid-ana5>3.0.co;2-i · Cited by 268
Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies
Darnell, R. B., & DeAngelis, L. M. (1993) · The Lancet · doi:10.1016/0140-6736(93)92485-c · Cited by 256
IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
Levine, T. D., & Pestronk, A. (1999) · Neurology · doi:10.1212/wnl.52.8.1701 · Cited by 250
Sillevis Smitt, P., Grefkens, J., de Leeuw, B., van den Bent, M., van Putten, W., Hooijkaas, H., & Vecht, C. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0706-4 · Cited by 249
Self-citationDalmau, J., Gultekin, S. H., Voltz, R., Hoard, R., DesChamps, T., Balmaceda, C., Batchelor, T., Gerstner, E., Eichen, J., Frennier, J., et al. (1999) · Brain · doi:10.1093/brain/122.1.27 · Cited by 236
Burt, R. K., Traynor, A. E., Pope, R., Schroeder, J., Cohen, B., Karlin, K. H., Lobeck, L., Goolsby, C., Rowlings, P., Davis, F. A., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3505 · Cited by 215
Graus, F., Dalmau, J., Valldeoriola, F., Ferrer, I., Reñé, R., Marin, C., Vecht, C. J., Arbizu, T., Targa, C., & Moll, J. W. B. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00205-6 · Cited by 206
Self-citationParaneoplastic cerebellar degeneration: A clinical and CT study
Greenberg, H. (1984) · Journal of Neuro-Oncology · doi:10.1007/bf00178121 · Cited by 204
Clinical outcome of patients with anti-Hu–associated encephalomyelitis after treatment of the tumor
Keime-Guibert, F., Graus, F., Broët, P., Reñé, R., Molinuevo, J. L., Ascaso, C., & Delattre, J. Y. (1999) · Neurology · doi:10.1212/wnl.53.8.1719 · Cited by 188
Graus, F., Vega, F., Delattre, J. Y., Bonaventura, I., Reñé, R., Arbaiza, D., & Tolosa, E. (1992) · Neurology · doi:10.1212/wnl.42.3.536 · Cited by 186
(1995) · Neurology · doi:10.1212/wnl.45.10.1873 · Cited by 169
Graus, F., Illa, I., Agusti, M., Ribalta, T., Cruz-Sanchez, F., & Juarez, C. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90198-g · Cited by 163
Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites
Manley, G. T., Smitt, P. S., Dalmau, J., & Posner, J. B. (1995) · Annals of Neurology · doi:10.1002/ana.410380117 · Cited by 163
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies
Benyahia, B., Liblau, R., Merle-B�ral, H., Tourani, J. M., Dalmau, J. O., & Delattre, J. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199902)45:2<162::aid-ana5>3.0.co;2-r · Cited by 158
Fathallah‐Shaykh, H. M., Wolf, S., Wong, E., Posner, J. B., & Furneaux, H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3451 · Cited by 146
Epidemiology of Hodgkin's disease
Cole, P. (1972) · JAMA · doi:10.1001/jama.222.13.1636 · Cited by 128
Wyburn-Mason, R. (1969) · BMJ · doi:10.1136/bmj.3.5665.302-c · Cited by 126
Antineuronal (anti‐Ri) antibodies in a patient with steroid‐responsive opsoclonus‐myoclonus
Dropcho, E. J., Kline, L. B., & Riser, J. (1993) · Neurology · doi:10.1212/wnl.43.1_part_1.207 · Cited by 93
Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome
Plonquet, A., Gherardi, R. K., Créange, A., Antoine, J.-C. G., Benyahia, B., Grisold, W., Drlicek, M., Dreyfus, P. A., Honnorat, J., Khouatra, C., et al. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00452-0 · Cited by 62
Graus, F., Gultekin, S. H., Ferrer, I., Reiriz, J., Alberch, J., & Dalmau, J. O. (1998) · Acta Neuropathologica · doi:10.1007/s004010050853 · Cited by 59
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Recommended diagnostic criteria for paraneoplastic neurological syndromes
Graus, F. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034447 · Cited by 1,610
Paraneoplastic Syndromes Involving the Nervous System
Darnell, R. B., & Posner, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023009 · Cited by 1,062
Paraneoplastic syndromes of the CNS
Dalmau, J., & Rosenfeld, M. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70060-7 · Cited by 873
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Pelosof, L. C., & Gerber, D. E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0099 · Cited by 773
Metadata
- Authors
- Shams’ili, S., Grefkens, J., de Leeuw, B., van den Bent, M., Hooijkaas, H., van der Holt, B., Vecht, C., & Sillevis Smitt, P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-06
- Volume
- 126
- Issue
- 6
- Pages
- 1409-1418
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2025325056
- Cited by
- 579
- References
- 34
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.